Thermo Fisher Scientific Inc. has agreed to acquire Clario Holdings Inc., a provider of digital endpoint data solutions for clinical trials, in a cash transaction valued at $8.875 billion. The deal includes potential additional earnout and other payments contingent on future performance.

Clario’s platform integrates clinical trial endpoint data from devices, sites, and patients, enabling pharmaceutical and biotechnology companies to digitally collect, manage, and analyze clinical evidence across all phases of drug development. The company says its technology has supported approximately 70% of U.S. Food and Drug Administration drug approvals over the past decade.

Clario’s offerings include electronic clinical outcome assessments (eCOA), medical imaging, cardiac and respiratory assessments, and wearable data capture technologies. The company employs roughly 4,000 people globally and is expected to generate approximately $1.25 billion in revenue for the full year 2025.

“Clario is an outstanding strategic fit, enabling faster, more informed drug development through differentiated technology and data intelligence solutions,” said Marc N. Casper, Chairman, President and CEO of Thermo Fisher Scientific. “At Thermo Fisher, we come to work every day thinking about how we can further advance our customers’ important work, and by adding these high-growth capabilities, we will deliver even deeper clinical insights to our customers and further accelerate the digital transformation of clinical research.”

Casper added, “We’ve long admired Clario and this acquisition underscores our disciplined capital deployment strategy, which has an outstanding track record of creating shareholder value. We look forward to welcoming Clario’s colleagues to Thermo Fisher.”

“This strategic transaction will power the continued expansion of Clario’s differentiated digital endpoint platform and proprietary suite of AI tools,” said Chris Fikry, M.D., CEO at Clario. “Thermo Fisher Scientific’s global scale and extensive relationships with key decision makers across large pharma and biotech will fuel expansion of our comprehensive clinical trial platform. We are certain this will benefit our clients and, ultimately, patients.”

Other Pharma Industry Acquisitions

Check out Contract Pharma’s Pharmaceutical Industry Mergers & Acquisitions Roundup.